1. Home
  2. KNDI vs SKYE Comparison

KNDI vs SKYE Comparison

Compare KNDI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNDI
  • SKYE
  • Stock Information
  • Founded
  • KNDI 2002
  • SKYE 2012
  • Country
  • KNDI China
  • SKYE United States
  • Employees
  • KNDI N/A
  • SKYE N/A
  • Industry
  • KNDI Auto Manufacturing
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • KNDI Consumer Discretionary
  • SKYE Health Care
  • Exchange
  • KNDI Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • KNDI 91.2M
  • SKYE 80.7M
  • IPO Year
  • KNDI N/A
  • SKYE N/A
  • Fundamental
  • Price
  • KNDI $1.15
  • SKYE $2.83
  • Analyst Decision
  • KNDI
  • SKYE Buy
  • Analyst Count
  • KNDI 0
  • SKYE 6
  • Target Price
  • KNDI N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • KNDI 117.3K
  • SKYE 183.9K
  • Earning Date
  • KNDI 03-13-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • KNDI N/A
  • SKYE N/A
  • EPS Growth
  • KNDI N/A
  • SKYE N/A
  • EPS
  • KNDI N/A
  • SKYE N/A
  • Revenue
  • KNDI $118,127,232.00
  • SKYE N/A
  • Revenue This Year
  • KNDI N/A
  • SKYE N/A
  • Revenue Next Year
  • KNDI N/A
  • SKYE N/A
  • P/E Ratio
  • KNDI N/A
  • SKYE N/A
  • Revenue Growth
  • KNDI N/A
  • SKYE N/A
  • 52 Week Low
  • KNDI $0.89
  • SKYE $2.31
  • 52 Week High
  • KNDI $2.98
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • KNDI 52.41
  • SKYE 47.49
  • Support Level
  • KNDI $1.06
  • SKYE $2.60
  • Resistance Level
  • KNDI $1.15
  • SKYE $3.54
  • Average True Range (ATR)
  • KNDI 0.06
  • SKYE 0.50
  • MACD
  • KNDI -0.00
  • SKYE 0.02
  • Stochastic Oscillator
  • KNDI 34.62
  • SKYE 21.51

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: